Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Florian Thaler & Saverio Minucci. (2011) Next generation histone deacetylase inhibitors: the answer to the search for optimized epigenetic therapies?. Expert Opinion on Drug Discovery 6:4, pages 393-404.
Read now
Read now
Paul A Marks. (2010) The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opinion on Investigational Drugs 19:9, pages 1049-1066.
Read now
Read now
Chunlei Zhang & Madeleine Duvic. (2010) Vorinostat for the treatment of cutaneous T-cell lymphoma. Expert Review of Dermatology 5:4, pages 393-401.
Read now
Read now
Articles from other publishers (47)
José Eduardo Guzmán Ramírez & Teresa Mancilla Percino. (2023)
Synthesis of N‐aminophalimides derived from α‐amino acids: Theoretical study to find them as
HDAC8
inhibitors by docking simulations and in vitro assays
. Chemical Biology & Drug Design 102:6, pages 1367-1386.
Crossref
Crossref
Guoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, Xiao Li, Kai Ran, Huan Feng, Tianwen Luo, Shuyan Zhou, Chang Su, Wei Wei, Ningyu Wang, Chao Gao, Lifeng Zhao & Luoting Yu. (2022) Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Cancer. Journal of Medicinal Chemistry 65:24, pages 16541-16569.
Crossref
Crossref
Liyun Zhao, Qi Liang, Ye He, Maoyu Liu, Rongsheng Tong, Zhongliang Jiang, Wenjing Wang & Jianyou Shi. (2022) HDAC/JAK dual target inhibitors of cancer-related targets: The success of nonclearable linked pharmacophore mode. Bioorganic Chemistry 129, pages 106181.
Crossref
Crossref
Dehua Lu, Cheng Wang, Lailiang Qu, Fucheng Yin, Shang Li, Heng Luo, Yonglei Zhang, Xingchen Liu, Xinye Chen, Zhongwen Luo, Ningjie Cui, Lingyi Kong & Xiaobing Wang. (2022) Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry 65:19, pages 12838-12859.
Crossref
Crossref
Xin-Chen Jiang, Fang-Hai Tu, Li-Yuan Wei, Bo-Zheng Wang, Hao Yuan, Jing-Mei Yuan, Yong Rao, Shi-Liang Huang, Qing-Jiang Li, Tian-Miao Ou, Hong-Gen Wang, Jia-Heng Tan, Shuo-Bin Chen & Zhi-Shu Huang. (2022) Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry 65:18, pages 12346-12366.
Crossref
Crossref
Hongbo Ma, Xuyi Wu, Yi Li & Yong Xia. (2022) Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology 13.
Crossref
Crossref
Hongbo Ma, Xuyi Wu, Yi Li & Yong Xia. (2022) Avances en la investigación de los mecanismos moleculares, los blancos terapéuticos y el desarrollo de fármacos para la fibrosis pulmonar idiopática. Kompass Neumología 4:3, pages 129-146.
Crossref
Crossref
Rajeev Kharb. (2021) Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development. Anti-Cancer Agents in Medicinal Chemistry 21:11, pages 1338-1349.
Crossref
Crossref
Taiping Chen, Hongwu Jiang, Jianjun Zhou, Zicheng Li, Wencai Huang, Youfu Luo & Yinglan Zhao. (2020) Synthesis of N-Substituted Benzamide Derivatives and their Evaluation as Antitumor Agents. Medicinal Chemistry 16:4, pages 555-562.
Crossref
Crossref
Dizhong Chen, Chang Kai Soh, Wei Huang Goh, Zilong Wang & Haishan Wang. (2020) Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors. Bioorganic Chemistry 98, pages 103724.
Crossref
Crossref
Nilanjan Adhikari, Sk Abdul Amin & Tarun Jha. (2018) Selective and nonselective HDAC8 inhibitors: a therapeutic patent review. Pharmaceutical Patent Analyst 7:6, pages 259-276.
Crossref
Crossref
Dizhong Chen, Chang Kai Soh, Wei Huang Goh & Haishan Wang. (2018) Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry 61:4, pages 1552-1575.
Crossref
Crossref
Lianbin Yao, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Prachi Singh, Minh-Dao Duong-Thi, Jeannie X. T. Lee, Pondy Murugappan Ramanujulu, Wee Joo Chng, Jeffrey J. Y. Yen, Sten Ohlson & Brian W. Dymock. (2017) Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. Journal of Medicinal Chemistry 60:20, pages 8336-8357.
Crossref
Crossref
Artur Gurgul, Jolanta Opiela, Klaudia Pawlina, Tomasz Szmatoła, Michał Bochenek & Monika Bugno-Poniewierska. (2017) The effect of histone deacetylase inhibitor trichostatin A on porcine mesenchymal stem cell transcriptome. Biochimie 139, pages 56-73.
Crossref
Crossref
Thea van den Bosch, Marcel Kwiatkowski, Rainer Bischoff & Frank J Dekker. (2017) Targeting transcription factor lysine acetylation in inflammatory airway diseases. Epigenomics 9:7, pages 1013-1028.
Crossref
Crossref
Vijaya Rao Pidugu, Nagendra Sastry Yarla, Srinivasa Rao Pedada, Arunasree M. Kalle & A. Krishna Satya. (2016) Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity. Bioorganic & Medicinal Chemistry 24:21, pages 5611-5617.
Crossref
Crossref
Samantha M. Gromek, James A. deMayo, Andrew T. Maxwell, Ashley M. West, Christopher M. Pavlik, Ziyan Zhao, Jin Li, Andrew J. Wiemer, Adam Zweifach & Marcy J. Balunas. (2016) Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. Bioorganic & Medicinal Chemistry 24:21, pages 5183-5196.
Crossref
Crossref
Xiaobin Li, Minghai Tang, Hairong Wang, Liang Ma, Haoyu Ye, Chunyu Wang, Qiunan Yang, Li Wan & Lijuan Chen. (2016) In Vitro and In Vivo Primary Metabolic Characterization of F18, a Novel Histone Deacetylase-6 (HDAC6) Inhibitor, Using UHPLC–QqQ–MS/MS and Q-TOF–MS Methods. Chromatographia 79:21-22, pages 1479-1490.
Crossref
Crossref
Mohammed Manal, M.J.N. Chandrasekar, Jeyapal Gomathi Priya & M.J. Nanjan. (2016) Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry 67, pages 18-42.
Crossref
Crossref
Yang Cai, Xiang Yan, Guoqing Zhang, Weihong Zhao & Shunchang Jiao. (2015) The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC. Oncotarget 6:22, pages 18997-19005.
Crossref
Crossref
Xuan Zhang, Yannan Kong, Jie Zhang, Mingbo Su, Yubo Zhou, Yi Zang, Jia Li, Yi Chen, Yanfen Fang, Xiongwen Zhang & Wei Lu. (2015) Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors. European Journal of Medicinal Chemistry 95, pages 127-135.
Crossref
Crossref
Subha Kalyaanamoorthy & Yi-Ping Phoebe Chen. (2014) Modelling and enhanced molecular dynamics to steer structure-based drug discovery. Progress in Biophysics and Molecular Biology 114:3, pages 123-136.
Crossref
Crossref
Tao You, Ke Chen, Fei-Hai Wang, Pi-Hong Li, Li-Yi Li, Zhi-Hao Wu, Kong-Hai Ni & Zhi-Qiang Zheng. (2014) Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors. Chinese Chemical Letters 25:3, pages 474-478.
Crossref
Crossref
M. Lemper, S. Snykers, T. Vanhaecke, K. De Paepe & V. Rogiers. (2014) Current Status of Healthy Human Skin Models: Can Histone Deacetylase Inhibitors Potentially Improve the Present Replacement Models?. Skin Pharmacology and Physiology 27:1, pages 36-46.
Crossref
Crossref
Xuan Zhang, Jie Zhang, Mingbo Su, Yubo Zhou, Yi Chen, Jia Li & Wei Lu. (2014) Design, synthesis and biological evaluation of 4′-demethyl-4-deoxypodophyllotoxin derivatives as novel tubulin and histone deacetylase dual inhibitors. RSC Adv. 4:76, pages 40444-40448.
Crossref
Crossref
Christopher M. Pavlik, Christina Y. B. Wong, Sophia Ononye, Dioxelis D. Lopez, Niclas Engene, Kerry L. McPhail, William H. Gerwick & Marcy J. Balunas. (2013)
Santacruzamate A, a Potent and Selective Histone Deacetylase Inhibitor from the Panamanian Marine Cyanobacterium cf.
Symploca
sp.
. Journal of Natural Products 76:11, pages 2026-2033.
Crossref
Crossref
Subha Kalyaanamoorthy & Yi-Ping Phoebe Chen. (2013) Ligand release mechanisms and channels in histone deacetylases. Journal of Computational Chemistry 34:26, pages 2270-2283.
Crossref
Crossref
Pia Larsson, Niklas Bergh, Emma Lu, Erik Ulfhammer, Mia Magnusson, Karin Wåhlander, Lena Karlsson & Sverker Jern. (2012) Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells. Journal of Thrombosis and Thrombolysis 35:2, pages 185-192.
Crossref
Crossref
Omika Katoch, BS Dwarakanath & Paban K Agrawala. (2013) HDAC inhibitors: applications in oncology and beyond. HOAJ Biology 2:1, pages 1.
Crossref
Crossref
C.J. Marmion, J.P. Parker & K.B. Nolan. 2013. Comprehensive Inorganic Chemistry II. Comprehensive Inorganic Chemistry II
683
708
.
Kosta SteliouMichael S. BoosalisSusan P. PerrineJosé SangermanDouglas V. Faller. (2012) Butyrate Histone Deacetylase Inhibitors. BioResearch Open Access 1:4, pages 192-198.
Crossref
Crossref
Giuseppe GianniniWalter Cabri, Caterina Fattorusso & Manuela Rodriquez. (2012) Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Medicinal Chemistry 4:11, pages 1439-1460.
Crossref
Crossref
Daniel M. Fass, Melissa M. Kemp, Frederick A. Schroeder, Florence F. Wagner, Qiu Wang & Edward B. Holson. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine.
Sophia N Ononye, Michael van Heyst, Eric M Falcone, Amy C Anderson & Dennis L Wright. (2012) Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer. Pharmaceutical Patent Analyst 1:2, pages 207-221.
Crossref
Crossref
Florian Thaler. (2012) Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. Pharmaceutical Patent Analyst 1:1, pages 75-90.
Crossref
Crossref
Berkley E Gryder, Quaovi H Sodji & Adegboyega K Oyelere. (2012) Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Medicinal Chemistry 4:4, pages 505-524.
Crossref
Crossref
Subha Kalyaanamoorthy & Yi-Ping Phoebe Chen. (2012) Exploring Inhibitor Release Pathways in Histone Deacetylases Using Random Acceleration Molecular Dynamics Simulations. Journal of Chemical Information and Modeling 52:2, pages 589-603.
Crossref
Crossref
Androniki Kretsovali, Christiana Hadjimichael & Nikolaos Charmpilas. (2012) Histone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming. Stem Cells International 2012, pages 1-10.
Crossref
Crossref
Francoise Halley, Jeanette Reinshagen, Bernhard Ellinger, Markus Wolf, Andrew L. Niles, Nathan J. Evans, Thomas A. Kirkland, Julia M. Wagner, Manfred Jung, Philip Gribbon & Sheraz Gul. (2011) A Bioluminogenic HDAC Activity Assay: Validation and Screening. SLAS Discovery 16:10, pages 1227-1235.
Crossref
Crossref
Cheng Wang, Leonhard M. Henkes, Leah B. Doughty, Min He, Difei Wang, Franz-Josef Meyer-Almes & Yi-Qiang Cheng. (2011) Thailandepsins: Bacterial Products with Potent Histone Deacetylase Inhibitory Activities and Broad-Spectrum Antiproliferative Activities. Journal of Natural Products 74:10, pages 2031-2038.
Crossref
Crossref
Haishan Wang, Niefang Yu, Dizhong Chen, Ken Chi Lik Lee, Pek Ling Lye, Joyce Wei Wei Chang, Weiping Deng, Melvin Chi Yeh Ng, Ting Lu, Mui Ling Khoo, Anders Poulsen, Kanda Sangthongpitag, Xiaofeng Wu, Changyong Hu, Kee Chuan Goh, Xukun Wang, Lijuan Fang, Kay Lin Goh, Hwee Hoon Khng, Siok Kun Goh, Pauline Yeo, Xin Liu, Zahid Bonday, Jeanette M. Wood, Brian W. Dymock, Ethirajulu Kantharaj & Eric T. Sun. (2011)
Discovery of (2
E
)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1
H
-benzimidazol-5-yl}-
N
-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile
. Journal of Medicinal Chemistry 54:13, pages 4694-4720.
Crossref
Crossref
Faith A.A. Kwa, Aneta Balcerczyk, Paul Licciardi, Assam El-Osta & Tom C. Karagiannis. (2011) Chromatin modifying agents – the cutting edge of anticancer therapy. Drug Discovery Today 16:13-14, pages 543-547.
Crossref
Crossref
Chas Bountra, Udo Oppermann & Tom D. Heightman. 2011. Molecular and Functional Models in Neuropsychiatry. Molecular and Functional Models in Neuropsychiatry
281
322
.
Hong Chul Yoon, Eunhyun Choi, Jung Eun Park, Misun Cho, Jeong Jea Seo, Soo Jin Oh, Jong Soon Kang, Hwan Mook Kim, Song-Kyu Park, Kiho Lee & Gyoonhee Han. (2010) Property based optimization of δ-lactam HDAC inhibitors for metabolic stability. Bioorganic & Medicinal Chemistry Letters 20:22, pages 6808-6811.
Crossref
Crossref
Paul A. Marks. (2010) Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 1799:10-12, pages 717-725.
Crossref
Crossref
Patrick M. Woster. 2010.
245
260
.
Roland W. Bürli, Elizabeth Thomas & Vahri Beaumont. 2010. Neurodegenerative Diseases. Neurodegenerative Diseases
1
56
.